Patent US3634901A successfully refreshed from Google Patents.
Patent US3078873A successfully refreshed from Google Patents.
Patent US4582810A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4582810A Expired / Lapsed US ⏱️ 0.0 years remaining

Immuno-agglutination particle suspensions

Assignee: Becton Dickinson and Co
•
Filing: 1983-09-30
•
Granted: 1986-04-15
•
Expires: 2003-09-30
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A suspension of diagnostic particles comprising antibody molecules attached to a carboxylate derivatized polymer core is provided for agglutination tests. The antibody is linked to the core through an avidin-biotin bridge. Avidin is joined by an amide bond to carboxyl groups on the core, and biotin is linked by an amide bond to amino groups on the antibody molecule. The core-bound antibody is exposed to a mixture of free biotin and biotinylated antibody to attach a controlled amount of antibody that is consistent with suspension stability prior to its use in a test and rapid cross-linking of suspended particles in the presence of antigen.

Inventors

  • 👤 Robert Rosenstein

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 09:57
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/54313; Y; Y10; Y10S; Y10S436/00; Y10S436/823; Y10T; Y10T436/00; Y10T436/25; Y10T436/25875

Claims Analysis

Total Claims: 32
Claim 1
Independent Claim 105 words
A diagnostic particle comprising a carboxylate-derivatized polymeric core between about 0.2 and about 1.0 micron in diameter, a plurality of avidin moieties linked through amide bonds to said core, a plurality of biotin moieties complexed to said avidin moieties, and a plurality of antibody molecules linked through amide bonds to a significant portion of said biotin moieties, the amount of antibody molecules on the surface of said particle being controlled so that said diagnostic particle may be stably suspended in aqueous medium in the presence of like particles without agglutination, but subsequently agglutinate in the presence of a substance with which said antibody molecules react.
Claim 2
Dependent Claim 105 words
A diagnostic particle comprising a carboxylate-derivatized polymeric core between about 0.2 and about 1.0 micron in diameter, a plurality of avidin moieties linked through amide bonds to said core, a plurality of biotin moieties complexed to said avidin moieties, and a plurality of antibody molecules linked through amide bonds to a significant portion of said biotin moieties, the amount of antibody molecules on the surface of said particle being controlled so that said diagnostic particle may be stably suspended in aqueous medium in the presence of like particles without agglutination, but subsequently agglutinate in the presence of a substance with which said antibody molecules react.
Claim 3
Dependent Claim 117 words
A diagnostic composition comprising a plurality of particles, each particle comprising a carboxylate-derivatized polymeric core between about 0.2 and about 1.0 micron in diameter, a plurality of avidin moieties linked through amide bonds to said core, a plurality of biotin moieties complexed to said avidin moieties and a plurality of antibody molecules linked through amide bonds to a significant portion of said biotin moieties and an aqueous medium in which said particles are suspended, the amount of antibody molecules on each of said particles being controlled so that said particles remain in suspension in said aqueous medium without agglutination, but when a substance reactive with said antibody molecules is introduced into said aqueous medium, said particles agglutinate.
Claim 4
Dependent Claim 117 words
A diagnostic composition comprising a plurality of particles, each particle comprising a carboxylate-derivatized polymeric core between about 0.2 and about 1.0 micron in diameter, a plurality of avidin moieties linked through amide bonds to said core, a plurality of biotin moieties complexed to said avidin moieties and a plurality of antibody molecules linked through amide bonds to a significant portion of said biotin moieties and an aqueous medium in which said particles are suspended, the amount of antibody molecules on each of said particles being controlled so that said particles remain in suspension in said aqueous medium without agglutination, but when a substance reactive with said antibody molecules is introduced into said aqueous medium, said particles agglutinate.
Claim 5
Dependent Claim 24 words
A composition according to claim 2 wherein said particles cores are formed of a polymer selected from the group consisting of polyacrylamide and polystyrene.
Claim 6
Dependent Claim 29 words
A composition according to claim 2 wherein said particles have between about 10 10 and about 10 13 avidin molecules per cm 2 of surface area of said cores.
Claim 7
Dependent Claim 29 words
A composition according to claim 2 wherein said particles have between about 2×10 11 and about 2×10 12 antibody molecules per cm 2 of surface area of said cores.
Claim 8
Dependent Claim 28 words
A composition according to claim 2 wherein said diagnostic particles have neutralizing moieties attached to core surface carboxyl groups that are not linked by amide bonds to avidin.
Claim 9
Dependent Claim 21 words
A composition according to claim 2 wherein said diagnostic particles also include non-immunogenic proteinaceous material adsorbed on surfaces of said cores.
Claim 10
Dependent Claim 14 words
A composition according to claim 2 wherein said antibody molecules are monoclonal antibody molecules.
Claim 11
Dependent Claim 24 words
A composition according to claim 2 wherein said cores are carboxylated to between about 0.1 to about 0.5 milliequivalents per gram of core particles.
Claim 12
Independent Claim 88 words
A method of preparing diagnostic particles comprising providing carboxylate-derivatized polymeric core particles between about 0.2 and about 1.0 micron in diameter, linking avidin molecules to said core particles through amide bonds, binding biotin molecules to antibody molecules through amide bonds, and complexing said core particle-linked avidin with a controlled amount of said antibody molecule-bound biotin, whereby said diagnotic particles may be suspended in aqueous medium without agglutination of said particles, but when a substance reactive with said antibody molecules is introduced into said aqueous medium, said particles agglutinate.
Claim 13
Independent Claim 88 words
A method of preparing diagnostic particles comprising providing carboxylate-derivatized polymeric core particles between about 0.2 and about 1.0 micron in diameter, linking avidin molecules to said core particles through amide bonds, binding biotin molecules to antibody molecules through amide bonds, and complexing said core particle-linked avidin with a controlled amount of said antibody molecule-bound biotin, whereby said diagnotic particles may be suspended in aqueous medium without agglutination of said particles, but when a substance reactive with said antibody molecules is introduced into said aqueous medium, said particles agglutinate.
Claim 14
Dependent Claim 24 words
A method according to claim 10, providing core particles which are carboxylated to between about 0.1 and about 0.5 milliequivalents per gram of polymer.
Claim 15
Dependent Claim 19 words
A method according to claim 10 wherein said polymer is selected from the group consisting of polystyrene and polyacrylamide.
Claim 16
Dependent Claim 30 words
A method according to claim 12 wherein said polymer is polystyrene, and between about 1.2×10 -3 and about 1.2×10 -2 gm of avidin are linked per gram of core particles.
Claim 17
Dependent Claim 30 words
A method according to claim 12 wherein said polymer is polyacrylamide and between about 1.2×10 -3 and about 1.2×10 -2 gm of avidin are linked per gram of core particles.
Claim 18
Dependent Claim 21 words
A method according to claim 10 wherein said avidin is selected from the group consisting of egg white avidin and streptavidin.
Claim 19
Dependent Claim 19 words
A method according to claim 10 including neutralizing surface carboxyl groups of said core particles not bound to avidin.
Claim 20
Dependent Claim 27 words
A method according to claim 16 including adsorbing a non-immunogenic proteinaceous material onto the surface of said core particles subsequent to avidin linking and carboxyl group neutralization.
Claim 21
Dependent Claim 29 words
A method according to claim 10 controlling the amount of antibody molecules by complexing said core particle-linked avidin with a mixture of free biotinic acid and said antibody-bound biotin.
Claim 22
Dependent Claim 32 words
A method according to claim 18 controlling the amount of antibody molecules to provide between about 2×10 11 and about 2×10 12 antibody molecules per cm 2 of core particles surface area.
Claim 23
Dependent Claim 25 words
A method according to claim 19 wherein the molar ratio of said biotinic acid and said antibody-bound biotin is between about 1:1 and about 10:1.
Claim 24
Dependent Claim 13 words
A method according to claim 10 wherein said antibody is a monoclonal antibody.
Claim 25
Dependent Claim 32 words
A method according to claim 10 wherein linking said avidin to said core particles comprises reacting said core particles with a carbodiimide to form an intermediate and reacting said intermediate with avidin.
Claim 26
Dependent Claim 34 words
A method according to claim 22 wherein linking said biotin to said antibody comprises reacting said antibody with an N-hydroxy imide to form an ester intermediate and reacting said antibody with said ester intermediate.
Claim 27
Dependent Claim 20 words
A method according to claim 10, including suspending said diagnostic particles in a liquid medium to form a stable suspension.
Claim 28
Dependent Claim 32 words
A diagnostic particle in accordance with claim 1 wherein said particle has between about 2×10 11 and about 2×10 12 antibody molecules per cm 2 of surface area of said polymeric core.
Claim 29
Dependent Claim 38 words
A diagnostic particle in accordance with claim 1 wherein said antibody molecules are linked to a first significant portion of said biotin moieties and a second significant portion of said biotin moieties have no antibody molecules linked thereto.
Claim 30
Dependent Claim 124 words
A diagnostic particle comprising a core between about 0.2 and about 1.0 micron in diameter formed of polymer selected from the group consisting of polyacrylamide and polystyrene, said polymer being carboxylated to between about 0.1 to about 0.5 milliequivalents per gram, between about 10 10 and about 10 13 avidin molecules bound through amide bonds to said core per cm 2 of surface area, neutralizing moieties attached to core surface carboxyl groups that are not linked by amide bonds to avidin, additional non-immunogenic proteinaceous material adsorbed on surfaces of said cores, biotin moieties complexed to said avidin moieties, and about 2×10 11 and about 2×10 12 antibody molecules linked through amide bonds to biotin moieties per cm 2 of surface area of said core.
Claim 31
Dependent Claim 124 words
A diagnostic particle comprising a core between about 0.2 and about 1.0 micron in diameter formed of polymer selected from the group consisting of polyacrylamide and polystyrene, said polymer being carboxylated to between about 0.1 to about 0.5 milliequivalents per gram, between about 10 10 and about 10 13 avidin molecules bound through amide bonds to said core per cm 2 of surface area, neutralizing moieties attached to core surface carboxyl groups that are not linked by amide bonds to avidin, additional non-immunogenic proteinaceous material adsorbed on surfaces of said cores, biotin moieties complexed to said avidin moieties, and about 2×10 11 and about 2×10 12 antibody molecules linked through amide bonds to biotin moieties per cm 2 of surface area of said core.
Claim 32
Dependent Claim 14 words
A suspension of diagnostic particles in accordance with claim 27 in an aqueous medium.

References Cited (Backward Citations)

US4419444A Cited
US4298685A Cited
US4228237A Cited
US4220565A Cited
US4276206A Cited
US4282287A Cited
US4352884A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-04-14 1989-10-14 1990-04-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-04-14 1993-10-14 1994-04-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-04-14 1997-10-14 1998-04-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag